vs
Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and VersaBank (VBNK). Click either name above to swap in a different company.
VersaBank is the larger business by last-quarter revenue ($26.7M vs $19.6M, roughly 1.4× STANDARD BIOTOOLS INC.). VersaBank runs the higher net margin — 30.3% vs -177.4%, a 207.7% gap on every dollar of revenue. On growth, VersaBank posted the faster year-over-year revenue change (31.2% vs -11.5%). Over the past eight quarters, VersaBank's revenue compounded faster (16.6% CAGR vs -12.2%).
Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.
VersaBank is a Canada-based digital-first financial institution offering commercial lending, high-interest deposit accounts and customized financial services for SMEs, retail clients and institutional partners across North America. It operates no physical branches, using secure digital infrastructure to deliver efficient, cost-effective banking experiences.
LAB vs VBNK — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $19.6M | $26.7M |
| Net Profit | $-34.7M | $8.1M |
| Gross Margin | 48.5% | — |
| Operating Margin | -168.5% | — |
| Net Margin | -177.4% | 30.3% |
| Revenue YoY | -11.5% | 31.2% |
| Net Profit YoY | -28.8% | 35.9% |
| EPS (diluted) | $-0.09 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.7M | ||
| Q3 25 | $19.6M | $23.1M | ||
| Q2 25 | $21.8M | $22.0M | ||
| Q1 25 | $40.8M | $20.3M | ||
| Q3 24 | $22.1M | $19.7M | ||
| Q2 24 | $22.5M | $20.8M | ||
| Q1 24 | $45.5M | $21.1M | ||
| Q4 23 | $28.2M | — |
| Q1 26 | — | $8.1M | ||
| Q3 25 | $-34.7M | $4.8M | ||
| Q2 25 | $-33.5M | $6.2M | ||
| Q1 25 | $-26.0M | $5.9M | ||
| Q3 24 | $-26.9M | $7.1M | ||
| Q2 24 | $-45.7M | $8.6M | ||
| Q1 24 | $-32.2M | $9.3M | ||
| Q4 23 | $-19.8M | — |
| Q1 26 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — | ||
| Q4 23 | 47.6% | — |
| Q1 26 | — | — | ||
| Q3 25 | -168.5% | — | ||
| Q2 25 | -118.1% | — | ||
| Q1 25 | -80.8% | — | ||
| Q3 24 | -120.9% | — | ||
| Q2 24 | -134.5% | — | ||
| Q1 24 | -132.2% | — | ||
| Q4 23 | -75.9% | — |
| Q1 26 | — | 30.3% | ||
| Q3 25 | -177.4% | 20.8% | ||
| Q2 25 | -153.7% | 28.3% | ||
| Q1 25 | -63.8% | 29.3% | ||
| Q3 24 | -122.0% | 35.9% | ||
| Q2 24 | -203.3% | 41.5% | ||
| Q1 24 | -70.6% | 44.0% | ||
| Q4 23 | -70.2% | — |
| Q1 26 | — | — | ||
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $-0.09 | — | ||
| Q1 25 | $-0.07 | — | ||
| Q3 24 | $-0.07 | — | ||
| Q2 24 | $-0.12 | — | ||
| Q1 24 | $-0.27 | — | ||
| Q4 23 | $-0.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $129.4M | $458.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $399.7M | $396.4M |
| Total Assets | $539.6M | $4.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $458.4M | ||
| Q3 25 | $129.4M | $336.0M | ||
| Q2 25 | $158.6M | $248.3M | ||
| Q1 25 | $150.9M | $282.3M | ||
| Q3 24 | $210.6M | $181.0M | ||
| Q2 24 | $269.8M | $145.1M | ||
| Q1 24 | $287.1M | $93.1M | ||
| Q4 23 | $51.7M | — |
| Q1 26 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — | ||
| Q4 23 | $63.5M | — |
| Q1 26 | — | $396.4M | ||
| Q3 25 | $399.7M | $385.5M | ||
| Q2 25 | $424.5M | $385.7M | ||
| Q1 25 | $454.6M | $380.5M | ||
| Q3 24 | $489.3M | $298.6M | ||
| Q2 24 | $510.3M | $292.1M | ||
| Q1 24 | $577.3M | $284.0M | ||
| Q4 23 | $-148.1M | — |
| Q1 26 | — | $4.5B | ||
| Q3 25 | $539.6M | $4.0B | ||
| Q2 25 | $557.0M | $3.7B | ||
| Q1 25 | $579.6M | $3.6B | ||
| Q3 24 | $681.5M | $3.3B | ||
| Q2 24 | $708.7M | $3.2B | ||
| Q1 24 | $777.7M | $3.1B | ||
| Q4 23 | $323.1M | — |
| Q1 26 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — | ||
| Q4 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.2M | $40.6M |
| Free Cash FlowOCF − Capex | $-23.1M | — |
| FCF MarginFCF / Revenue | -118.1% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | — | 5.03× |
| TTM Free Cash FlowTrailing 4 quarters | $-111.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $40.6M | ||
| Q3 25 | $-22.2M | — | ||
| Q2 25 | $-20.7M | — | ||
| Q1 25 | $-30.3M | $-65.0M | ||
| Q3 24 | $-27.9M | — | ||
| Q2 24 | $-39.0M | — | ||
| Q1 24 | $-62.5M | $-13.2M | ||
| Q4 23 | $-14.1M | — |
| Q1 26 | — | — | ||
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | — | ||
| Q3 24 | $-30.1M | — | ||
| Q2 24 | $-41.0M | — | ||
| Q1 24 | $-63.3M | — | ||
| Q4 23 | $-14.1M | — |
| Q1 26 | — | — | ||
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | — | ||
| Q3 24 | -136.4% | — | ||
| Q2 24 | -182.2% | — | ||
| Q1 24 | -138.9% | — | ||
| Q4 23 | -50.2% | — |
| Q1 26 | — | — | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 1.7% | — | ||
| Q4 23 | 0.3% | — |
| Q1 26 | — | 5.03× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -10.94× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.43× | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
VBNK
Segment breakdown not available.
